
A top-10 list of critical legal issues that biotech start-ups should make an effort to address, even when the capital squeeze is intense.
Judith Toffenetti is a partner at McDermott Will & Emery
A top-10 list of critical legal issues that biotech start-ups should make an effort to address, even when the capital squeeze is intense.
Published: November 1st 2008 | Updated: